Breaking Bank of England Holds Key Interest Rate Steady for Fifth Time Venezuelan Acting President Discusses Post-Maduro Vision in TIME Interview EU Invests 10 Billion Euros in AI Gigafactories to Boost Technological Independence Ebola Outbreak in Eastern Congo Becomes Fastest Growing in History AP-NORC Poll: Majority of Americans Believe War in Iran Not Worth Fighting

Thursday July 30, 2026

Reporter

NanoViricides

4Articles Published

4Communities Covered

Published Articles

Press Release

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Jul 28

Press Release

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

Jul 24

Press Release

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

Jul 23

Press Release

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

Jul 22